Holen Sie sich die Stockscreener-App
445.26
1.13%
-5.9706
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$451.23
Offen:
$454.24
24-Stunden-Volumen:
142.78K
Relative Volume:
0.14
Marktkapitalisierung:
$115.74B
Einnahmen:
$10.63B
Nettoeinkommen (Verlust:
$-479.80M
KGV:
33.40
EPS:
13.33
Netto-Cashflow:
$-1.35B
1W Leistung:
-7.81%
1M Leistung:
-6.68%
6M Leistung:
+0.94%
1J Leistung:
+25.75%
1-Tages-Spanne:
$445.00
$455.43
1-Wochen-Bereich:
$445.00
$479.94
52-Wochen-Spanne:
$346.29
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VRTX | 445.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 736.17 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 583.62 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.25 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
PNC Financial Services Group Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded to "Buy" Rating by StockNews.com - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Lifted by Advisors Asset Management Inc. - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Portfolio Design Labs LLC - MarketBeat
EULAV Asset Management Has $14.65 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jennison Associates LLC - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Trimmed by MWA Asset Management - MarketBeat
57,825 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Segall Bryant & Hamill LLC - MarketBeat
Northwest Bancshares Inc. Has $6.10 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Strategy Asset Managers LLC Sells 1,805 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Pathstone Holdings LLC Purchases 2,112 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Quest Partners LLC - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by W.G. Shaheen & Associates DBA Whitney & Co - MarketBeat
1,424 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Whalen Wealth Management Inc. - MarketBeat
First Turn Management LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Thrivent Financial for Lutherans Sells 3,119 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by OneDigital Investment Advisors LLC - MarketBeat
Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Braun Stacey Associates Inc. - MarketBeat
3 Growth Stocks You Can Buy Right Now Without Any Hesitation - The Motley Fool
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Swiss National Bank - MarketBeat
Atlanta Consulting Group Advisors LLC Purchases 1,331 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Empowered Funds LLC Sells 17,482 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Natixis Advisors LLC - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Lifted by Mizuho Securities USA LLC - MarketBeat
Kentucky Retirement Systems Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
CIBC Asset Management Inc Acquires 4,432 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Impax Asset Management Group plc Has $3.46 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Broderick Brian C Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Huntington National Bank - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by Citigroup - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Increased by KBC Group NV - MarketBeat
Citigroup Initiates Coverage of Vertex Pharmaceuticals (VRTX) with Buy Recommendation - MSN
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gilead, Vertex initiated as new big biotech buys at Citi - Seeking Alpha
Vertex Pharmaceuticals Shows Rising Relative Strength; Still Shy Of Key Benchmark - MSN
Sivik Global Healthcare LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Aubrey Capital Management Ltd Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Pinnacle Financial Partners Inc Grows Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex’s upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain - STAT
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline tests - Investing.com
Insider Sale at Vertex Pharmaceuticals Inc (VRTX) by EVP & CFO C - GuruFocus.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Chase Investment Counsel Corp Has $3.28 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Victory Capital Management Inc. Lowers Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Aptus Capital Advisors LLC Buys 3,071 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Baillie Gifford & Co. Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):